BioXcel Therapeutics, Inc. and its affiliated debtors are moving forward with their Chapter 11 bankruptcy reorganization plan, with a key court hearing scheduled for early December. On October 21, 2026, the United States Bankruptcy Court for the District of Delaware issued an order conditionally approving the company’s Second Amended Combined Disclosure Statement and Chapter 11 Plan for solicitation purposes. This approval authorizes the debtors to begin soliciting votes from creditors on the reorganization plan.
The combined hearing to consider final approval of the plan’s adequacy and to confirm the Chapter 11 plan is set for December 3, 2026, at 11:00 a.m. Eastern Time before Judge Thomas M. Horan in Wilmington, Delaware. The hearing will address whether the court will grant final confirmation of the plan as presented.
Key deadlines have been established for interested parties. The court set October 23, 2026, as the voting record date, determining which creditors are eligible to vote on the plan. Those entitled to vote have received ballots and specific instructions on how to submit them, with votes due no later than November 20, 2026, by 4:00 p.m. Eastern Time. Failure to follow the voting procedures could disqualify ballots.
Creditors and other stakeholders wishing to object to the plan or its disclosure statement must file and serve their objections by November 23, 2026, at 4:00 p.m. Eastern Time. Objections must be submitted in writing and comply with applicable bankruptcy rules, clearly outlining the basis for the opposition and, where possible, offering proposed modifications that could resolve concerns.
The debtors plan to file a Plan Supplement by November 13, 2026, containing additional documents related to the reorganization effort. While not all interested parties will receive direct copies of the supplement, it will be accessible through the designated solicitation agent’s website.
The reorganization plan includes important provisions related to releases, exculpations, and injunctions, including third-party releases, which could affect the rights of creditors and other parties involved in the case. Stakeholders are advised to carefully review these terms to understand their potential impact.
Information and documents related to the bankruptcy case, including the combined disclosure statement, plan, and court orders, are available at no cost through the solicitation agent’s website or from the court clerk’s office. Additional copies may be requested via phone, email, or mail.
This Chapter 11 filing is part of BioXcel Therapeutics’ ongoing efforts to restructure its financial obligations and emerge from bankruptcy in a viable position. The court’s upcoming confirmation hearing will be a critical step in determining the future of the company’s reorganization plan.